BRAF-Mutated Colorectal Cancer: What Is the Optimal Strategy for Treatment?
about
Effects of PHA-665752 and vemurafenib combination treatment on in vitro and murine xenograft growth of human colorectal cancer cells with BRAFV600E mutations.Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer.BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers.Mechanisms and Therapy for Cancer Metastasis to the Brain.
P2860
BRAF-Mutated Colorectal Cancer: What Is the Optimal Strategy for Treatment?
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
BRAF-Mutated Colorectal Cancer: What Is the Optimal Strategy for Treatment?
@en
type
label
BRAF-Mutated Colorectal Cancer: What Is the Optimal Strategy for Treatment?
@en
prefLabel
BRAF-Mutated Colorectal Cancer: What Is the Optimal Strategy for Treatment?
@en
P2093
P2860
P1476
BRAF-Mutated Colorectal Cancer: What Is the Optimal Strategy for Treatment?
@en
P2093
Aimery de Gramont
Anna Pellat
Chantal Dreyer
Magali Svrcek
Pascale Cervera
P2860
P2888
P356
10.1007/S11864-017-0453-5
P577
2017-02-01T00:00:00Z
P6179
1083848486